Form 4: Clene Inc. CFO Acquires 20,000 Stock Options

Clene Inc.'s Chief Financial Officer, Morgan R. Brown, was granted 20,000 stock options on February 24, 2025, according to a Form 4 filing with the SEC.

Summary

• On February 24, 2025, Morgan R. Brown, the Chief Financial Officer of Clene Inc., was granted 20,000 stock options.
• These options are exercisable for common stock at a price of $4.23 per share.
• The options were granted under the Clene Inc. Amended 2020 Stock Plan.
• 25% of the options vest on February 24, 2026, with the remaining options vesting in 36 equal monthly installments starting March 24, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of stock options, which is neither particularly positive nor negative on its own.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The vesting schedule of these options is fairly typical, with an initial cliff followed by monthly vesting.
• Comparing the size of the grant to similar companies would require further analysis of Clene Inc.'s compensation policies and market capitalization.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the CFO.
• Employees may see the grant as a sign of the company's commitment to its leadership.

Key Dates